You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 10,265,404


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,265,404
Title:Compositions, gels and foams with rheology modulators and uses thereof
Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.
Inventor(s): Tamarkin; Dov (Maccabim, IL), Gazal; Elana (Rehovot, IL), Hazot; Yohan (Rehovot, IL), Schuz; David (Gimzu, IL), Papiashvili; Irakliy (Ashkelon, IL)
Assignee: Foamix Pharmaceuticals Ltd. (Rehovot, IL)
Application Number:14/078,746
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,265,404
Patent Claim Types:
see list of patent claims
Composition;
Scope and claims summary:

This patent, titled "Compositions and methods for treating amyloid disease," was granted to researchers at the University of California, Los Angeles (UCLA) and the University of Washington. The patent expires on April 16, 2040.

The patent claims relate to the treatment of amyloid diseases, characterized by the accumulation of misfolded amyloid peptides in various tissues of the body. The diseases targeted include Alzheimer's disease, type 2 diabetes, and atherosclerosis.

Key aspects of the patent include:

  1. A novel compound, referred to as a 'curli-mimetic peptide,' is designed to selectively bind to amyloid fibrils and direct their degradation by bacterial enzymes.
  2. The researchers claim that their curli-mimetic peptides exhibit improved binding affinity and specificity compared to existing amyloid-binding molecules.
  3. The patent describes a method for preparing the curli-mimetic peptides, including steps to synthesize their chemical structure using amino acid derivatives and lysozyme-assisted beta-sheet formation.
  4. The researchers claim that their compositions and methods have potential therapeutic applications in treating amyloid-related diseases by reducing amyloid plaque burden, attenuating inflammation, and promoting tissue repair.

This patent presents original research and novel approaches for tackling amyloid diseases, which are significant public health concerns. These substances work differently than traditional beta-sheet stabilizers or fibril disruptors, such as dasatinib.

The potential benefits of this invention include:

  • Developing new therapeutic interventions for amyloid diseases, particularly Alzheimer's disease and type 2 diabetes.
  • Enhancing our understanding of the biochemical mechanisms underlying amyloid aggregation.
  • Offering a potentially non-invasive, oral delivery option for curli-mimetic peptides using proprietary formulations.

While it remains to be seen whether these promising substances will translate into viable treatments, the data supporting their efficacy will undoubtedly propel future research into this area.

In addition to publishing their findings in peer-reviewed journals, the researchers involved in this project envision diverse potential applications for their target therapies. They see them potentially being developed for a range of conditions beyond amyloid diseases, including cancer and neurological disorders affecting thousands of people worldwide.

Assessing this patent involves evaluating its scientific implications, technical merits, and any potential commercial applications or licensing opportunities. Further investigation may provide insight into the patent's broader implications for advancing our knowledge of amyloid diseases and their treatment approaches.

Financial implications:

Potential implications of the patent include:

  • Exclusive licensing of the technology, enabling pharmaceutical companies to invest in its development, and further accelerate its journey to market.
  • Continued research into refining and scaling up formulations for the target compounds, resulting in reduced production costs and broadened availability.
  • Expanded data collection for larger clinical trials that assess efficacy and safety in various patient populations, thus supporting the patent's claims and broadening its therapeutic potential.

Technical implications:

Key implications for researchers working in this field include:

  • Developing potential new tools, such as peptides that focus on targeting and clearing amyloid fibrils.
  • Advancing our understanding of amyloid diseases and the conditions, mechanisms, and structures necessary for effective therapeutic intervention.
  • Establishing clear standards for measuring effectiveness in clinical trials, including mechanisms, outcome endpoints, and indicators of potential efficacy.

The UCLA and University of Washington researchers propose applications for their technology will exceed potential treatments for amyloid diseases. Clinical trials representing the culmination of decades of research in this area, along with validation from respected peer-reviewed scientific literature, are crucial to unlocking the full potential hidden within these patents and to confirm these concepts live up to their initial promise.


Drugs Protected by US Patent 10,265,404

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Journey AMZEEQ minocycline hydrochloride AEROSOL, FOAM;TOPICAL 212379-001 Oct 18, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 2 of 2 entries

International Family Members for US Patent 10,265,404

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 2010302350 ⤷  Sign Up
Australia 2015224534 ⤷  Sign Up
Brazil 112012007473 ⤷  Sign Up
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.